AstraZeneca: Farxiga for Heart Failure with Reduced Ejection Fraction
AstraZeneca (AZN) has good news. Many of them are extremely positive. However, the firm’s stock is still struggling to get this pharmaceutical company out of the oversold territory where it has been living since the beginning of the year.
Among the recent good news came the results from a Phase 3 trial using AstraZeneca’s SGLT2 inhibitor product Farxiga for patients with reduced ejection fracture, with and without Type-2 diabetes. The trial known as DAPA-HF met the primary composite endpoint with a statistically significant and clinically meaningful reduction of cardiovascular death or the worsening of heart failure compared to placebo.
According to AstraZeneca Farxiga is the first in its class to show efficacy and safety data for patients with heart failure, with and without Type-2 diabetes, on top of standard of care.